卡培他滨节拍化疗联合芳香化酶抑制剂一线治疗HR+

卡培他滨节拍化疗联合芳香化酶抑制剂一线治疗HR+/HER2一转移性乳腺癌的成本-效用分析

http://www.100md.com 2025年9月2日中国药房 2025年第15期

     中图分类号R956；R979.1 文献标志码A 文章编号 1001-0408(2025)15-1893-06

    DOI 10.6039/j.issn.1001-0408.2025.15.13

    Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as firstline treatment for HR+/HER2- metastatic breast cancer

    ZHANG Ranran’，LIU Guoqiang1，ZHANG Yuxi'，GAO Shengnan2，GAO Ningl，FENG Bing1，LIU Ran1，LI Qian' (1.Dept.of Clinical Pharmacy，Hebei Medical University Third Hospital，Shijiazhuang O50051，China; 2. Hebei Society for Integrated Drug and Health Technology Assessment，Shijiazhuang O5O051，China)

    ABSTRACTOBJECTIVETo evaluate thecost-effectivenessof capecitabine metronomic chemotherapycombined witharomatase inhibitor(AI) versus AI monotherapy as first-line treatment for hormone receptor-positive ( HR+ )/human epidermal growth factor receptor 2-negative (HER2- )metastatic breast cancer，thereby providing evidence-based support for clinical therapeutic decisionmakingand healthcarepolicyformulation.METHODSBasedonthe MECCAtrial，aparitionedsurvivalmodelwasconstructed usinga4-weekcyclelength tosimulateoutcomesoverpatients’lifetime.Themodeloutputsincludedtotalcosts ......

百拇医药网 http://www.100md.com/html/paper/1001-0408/2025/15/008.htm

您现在查看是摘要页，全文长 20103 字符。